This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for Berkshire Hathaway, Pfizer & Danaher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Pfizer (PFE) and Danaher (DHR).
Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
by Zacks Equity Research
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC
by Zacks Equity Research
The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.
SNY or PFE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNY vs. PFE: Which Stock Is the Better Value Option?
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
by Kinjel Shah
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
by Zacks Equity Research
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill
by Zacks Equity Research
Glaxo's (GSK) phase III study, evaluating the efficacy of switching to Dovato from a three-drug TAF based regimen, meets the primary endpoint.
Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
by Zacks Equity Research
FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications
Aerie Completes Enrollment Under Rhopressa Study in Japan
by Zacks Equity Research
Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $43.37, moving +0.16% from the previous trading session.
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study
by Zacks Equity Research
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
by Zacks Equity Research
BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.
Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status
by Zacks Equity Research
Glaxo's (GSK) long-acting, injectable two-drug regimen gets FDA's priority review designation. The company begins study to identify approaches to implementing once-monthly injectable HIV treatment in the real world.
Women Health a Top Priority Now: 3 Stocks to Watch
by Sreyoshi Mukherjee
Women's healthcare gains global importance, investors might want to keep an eye on these stocks.
Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs
by Kinjel Shah
Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.
Dow 30 Stock Roundup: Visa to Buy Verifi, Goldman May Launch Own Cryptocurrency
by Swarup Gupta
The index enjoyed a holiday-shortened but successful week, buoyed by rate cut hopes and a reduction in trade tensions.
Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III
by Zacks Equity Research
Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $44.40 in the latest trading session, marking a +0.41% move from the prior day.
Will the Pharma Space Witness More Mega-Merger Deals in 2H?
by Kinjel Shah
After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.
Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis
by Zacks Equity Research
Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.
Company News for Jul 2, 2019
by Zacks Equity Research
Companies In The News Are: BA,GWR,BIP,PFE,COTY
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.
Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
by Zacks Equity Research
Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.
Company News for Jul 1, 2019
by Zacks Equity Research
Companies In The News Are: PFE,NKE,AAPL,STZ